diallyl disulfide has been researched along with Fatty Liver, Nonalcoholic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, G; Guo, J; Huang, M; Lei, Y; Lei, Z; Li, S; Liu, S; Liu, Y; Wang, Q; Wu, H; Yang, C; Yang, F; Yang, L; Yang, Y; Zhang, X | 1 |
| Li, G; Liu, B; Wang, Y; Xin, S; Xu, K; Zhang, J; Zhang, N | 1 |
2 other study(ies) available for diallyl disulfide and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Fatty liver and alteration of the gut microbiome induced by diallyl disulfide.
Topics: Allyl Compounds; Animals; Antioxidants; Disulfides; Garlic; Gastrointestinal Microbiome; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Signal Transduction; Triglycerides | 2019 |
Diallyl disulfide attenuates non‑alcoholic steatohepatitis by suppressing key regulators of lipid metabolism, lipid peroxidation and inflammation in mice.
Topics: Allyl Compounds; Animals; Disease Models, Animal; Disulfides; Inflammation; Lipid Metabolism; Lipid Peroxidation; Liver; Male; Mice, Inbred C57BL; NF-kappa B; Non-alcoholic Fatty Liver Disease; Signal Transduction | 2019 |